{"nctId":"NCT04085367","briefTitle":"Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face","startDateStruct":{"date":"2019-09-30","type":"ACTUAL"},"conditions":["Actinic Keratoses"],"count":557,"armGroups":[{"label":"MAL 16.8% Cream","type":"EXPERIMENTAL","interventionNames":["Drug: MAL 16.8% cream"]},{"label":"MAL Vehicle Cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: MAL Vehicle Cream"]}],"interventions":[{"name":"MAL 16.8% cream","otherNames":["CD06809-41"]},{"name":"MAL Vehicle Cream","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants aged â‰¥ 18 years at the Screening visit.\n* Participants had at least 4, but no more than 12, clinically-confirmed thin or moderately thick, non-hyperkeratotic, non-pigmented AKs located on the face (e.g., forehead, cheek, chin), and balding scalp.\n* Female Participants of non-childbearing potential.\n* Participants fully understood and signed an ICF before any investigational procedure(s) are performed.\n\nExclusion Criteria:\n\n* Participants with pigmented AK in the treatment areas.\n* Female participants who were pregnant, nursing, or planning a pregnancy during the study.\n* Participants with a clinical diagnosis of a skin disease other than AK.\n* Immunocompromised participants.\n* Participants with any condition that may be associated with a risk of poor protocol compliance.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Response at Week 12","description":"Complete response was defined as clearance of all AK lesion treated, at week 12 after the last Daylight photodynamic therapy (DL-PDT).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lesion Complete Response at Week 12","description":"Lesion complete response was defined as percent reduction from baseline in the number of cleared treated lesions, at 12 weeks after the last DL-PDT treatment. This outcome measure was analyzed as an intra-individual comparison between MAL cream and Vehicle cream.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.1","spread":"1.79"},{"groupId":"OG001","value":"-49.4","spread":"2.45"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Response at Week 12","description":"Participants achieving partial response was defined as participants with 75% or greater reduction from baseline in the number of cleared treated lesions, at 12 weeks after the last DL-PDT treatment, comparing MAL cream with vehicle cream.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"35.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":364},"commonTop":["Actinic keratosis","Application site pain","Application site erythema","Post procedural haemorrhage","Application site dermatitis"]}}}